dc.contributor
Institut Català de la Salut
dc.contributor
[Rua-Figueroa I] Rheumatology, Complejo Hospitalario Doctor Negrin, Las Palmas de Gran Canaria, Spain. [Cervera R] Hospital Clinic of Barcelona, Barcelona, Spain. [Freire-González M] Rheumatology, University Hospital Complex of A Coruña, A Coruña, Spain. [Turrión Nieves AI] Department of Rheumatology, Hospital Universitario de Salamanca, Salamanca, Spain. [Cortés-Hernández J] Servei de Reumatologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Castellvi I] Department of Rheumatology, Hospital Universitari de Santa Creu i Sant Pau, Barcelona, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Cervera, Ricard
dc.contributor.author
Freire-González, Mercedes
dc.contributor.author
Turrión Nieves, Ana Isabel
dc.contributor.author
Rua Figueroa, Iñigo
dc.contributor.author
Cortes Hernandez, Josefina
dc.contributor.author
Castellvi, Ivan
dc.date.accessioned
2025-10-24T10:17:54Z
dc.date.available
2025-10-24T10:17:54Z
dc.date.issued
2025-09-16T11:32:54Z
dc.date.issued
2025-09-16T11:32:54Z
dc.date.issued
2025-07-22
dc.identifier
Rua-Figueroa I, Cervera R, Freire-González M, Nieves AIT, Cortés-Hernández J, Castellvi I, et al. Oral glucocorticoid patterns use in moderate to severe active SLE: insights from the Spanish SPOCS data. Lupus Sci Med. 2025 Jul 22;12(2):e001597.
dc.identifier
http://hdl.handle.net/11351/13663
dc.identifier
10.1136/lupus-2025-001597
dc.identifier
001538019900001
dc.identifier.uri
https://hdl.handle.net/11351/13663
dc.description.abstract
Glucocorticoids; Lupus erythematosus systemic; Patient reported outcome measures
dc.description.abstract
Glucocorticoides; Lupus eritematós sistèmic; Mesures de resultats informades pels pacients
dc.description.abstract
Glucocorticoides; Lupus eritematoso sistémico; Medidas de resultados informadas por los pacientes
dc.description.abstract
This analysis has been funded by AstraZeneca Farmaceutica Spain
dc.format
application/pdf
dc.relation
Lupus Science & Medicine;12(2)
dc.relation
https://doi.org/10.1136/lupus-2025-001597
dc.rights
Attribution-NonCommercial 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Glucocorticoides - Ús terapèutic - Efectes secundaris
dc.subject
Lupus eritematós sistèmic - Tractament
dc.subject
CHEMICALS AND DRUGS::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Adrenal Cortex Hormones::Glucocorticoids
dc.subject
Other subheadings::Other subheadings::Other subheadings::/adverse effects
dc.subject
DISEASES::Skin and Connective Tissue Diseases::Connective Tissue Diseases::Lupus Erythematosus, Systemic
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::hormonas, sustitutos de hormonas y antagonistas de hormonas::hormonas::hormonas de la corteza suprarrenal::glucocorticoides
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/efectos adversos
dc.subject
ENFERMEDADES::enfermedades de la piel y tejido conjuntivo::enfermedades del tejido conjuntivo::lupus eritematoso sistémico
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.title
Oral glucocorticoid patterns use in moderate to severe active SLE: insights from the Spanish SPOCS data
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
